



## Advances in Prognosis and Theranostics of Lung Cancer

Guest Editors:

### Dr. Sudip Mukherjee

Department of Bioengineering,  
Rice University, 6500 Main Street,  
Houston, TX 77005, USA

### Dr. Manash Paul

Division of Pulmonary and  
Critical Care Medicine, David  
Geffen School of Medicine, The  
University of California, Los  
Angeles (UCLA), Los Angeles, CA  
90095, USA.

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editors

Dear Colleagues,

Lung cancer is one of the leading causes of cancer-related death worldwide. As per the recent cancer statistics data, lung cancer accounts for an estimated 2.1 million lung cancer cases and 1.8 million deaths in 2018. Lung cancer recurs following surgery in approximately 30% of patients and therefore has long been the number-one cause of death from cancer.

Hence alternative prognostic, therapeutic, and diagnostic approaches are required to reduce overall mortality and improve patient quality of life. In this present issue, we will publish research, reviews, and short communications on the modern approaches to combat lung cancer. Contributions on biomarker discovery, diagnosis, therapeutic modalities including immunotherapy, cancer vaccines, biomaterials-based theranostics approaches, nanomedicine-based theranostics, small molecule-based targeting, immunomodulatory approaches and other emergent approaches in precision oncology are also encouraged.

Dr. Sudip Mukherjee

Dr. Manash Paul

Guest Editors





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)